CAS 417716-92-8

Lenvatinib

Description:

Lenvatinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, including thyroid cancer and renal cell carcinoma. It works by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, and RET. Lenvatinib is characterized by its chemical formula, which reflects its complex structure, and it typically appears as a white to off-white solid. The substance has a moderate solubility in organic solvents and is generally administered orally in capsule form. Its pharmacokinetics indicate a relatively long half-life, allowing for once-daily dosing. Lenvatinib's efficacy is often evaluated in clinical settings, where it has shown significant improvements in progression-free survival compared to placebo in various studies. However, like many cancer therapies, it may be associated with side effects, including hypertension, fatigue, and gastrointestinal disturbances. Overall, lenvatinib represents a targeted therapeutic approach in oncology, reflecting advancements in personalized medicine.

Formula: C₂₁H₁₉ClN₄O₄

InChI: InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)

InChI key: InChIKey=WOSKHXYHFSIKNG-UHFFFAOYSA-N

SMILES: O(C=1C2=C(C=C(OC)C(C(N)=O)=C2)N=CC1)C3=CC(Cl)=C(NC(NC4CC4)=O)C=C3

Synonyms:

• 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide
• 4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
• 4-{3-Chloro-4-[(Cyclopropylcarbamoyl)Amino]Phenoxy}-7-Methoxyquinoline-6-Carboxamide
• 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-
• E 7080
• Er 203492-00
• Lenvanix
• Lenvatinib

4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide

CAS: 417716-92-8

Formula: C₂₁H₁₉ClN₄O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 426.8530

Ref: IN-DA00379E

Lenvatinib

CAS: 417716-92-8

Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity.

Formula: C₂₁H₁₉ClN₄O₄

Purity: 98.46% - 99.96%

Color and Shape: Solid

Molecular weight: 426.85

Ref: TM-T0520

Lenvatinib

CAS: 417716-92-8

Formula: C₂₁H₁₉ClN₄O₄

Color and Shape: Off-White Solid

Molecular weight: 426.86

Ref: 4Z-L-124001

Lenvatinib-d4

CAS: 417716-92-8

Formula: C₂₁H₁₅D₄ClN₄O₄

Color and Shape: Pink Solid

Molecular weight: 430.88

Ref: 4Z-L-124004

Lenvatinib

CAS: 417716-92-8

Lenvatinib

Purity: ≥98%

Molecular weight: 426.85g/mol

Ref: 54-BUP10975

Lenvatinib

CAS: 417716-92-8

Color and Shape: Neat

Ref: 86-MM3934.00

E7080

CAS: 417716-92-8

Ref: 7W-GW2433

Lenvatinib-d5

Controlled Product

CAS: 417716-92-8

Applications Lenvatinib-d5 is labelled Lenvatinib (L329400) which is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.
References Matsui, J., et al.: Clin. Cancer Res., 14, 5459 (2008); Gild, M., et al.: Nature Rev. Endocrinol., 7, 617 (2011)

Formula: C₂₁H₁₄D₅ClN₄O₄

Color and Shape: Light Red

Molecular weight: 431.88

Ref: TR-L329402

Lenvatinib

Controlled Product

CAS: 417716-92-8

Applications Lenvatinib is an orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.
References Matsui, J., et al.: Clin. Cancer Res., 14, 5459 (2008); Gild, M., et al.: Nature Rev. Endocrinol., 7, 617 (2011)

Formula: C₂₁H₁₉ClN₄O₄

Color and Shape: White To Beige

Molecular weight: 426.85

Ref: TR-L329400

Lenvatinib base - Bio-X ™

CAS: 417716-92-8

Lenvatinib is a tyrosine kinase inhibitor that is used to treat cancers such as solid tumours. This drug inhibits the activity of VEGR receptors. It also inhibits other receptors such as fibroblast growth factor.

Formula: C₂₁H₁₉ClN₄O₄

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 426.85 g/mol

Ref: 3D-BL164616

Lenvatinib base

CAS: 417716-92-8

VEGFR2 and VEGFR3 tyrosine kinase inhibitor

Formula: C₂₁H₁₉ClN₄O₄

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 426.85 g/mol

Ref: 3D-FC75063